Trial Profile
A 3-Day Monotherapy Study to Evaluate the Safety, Pharmacokinetic (PK) and Antiviral Activity of Velpatasvir in Patients with Genotype 1, 2, 3, or 4 Hepatitis C Virus (HCV) infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2015
Price :
$35
*
At a glance
- Drugs Velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 08 Dec 2015 New trial record